Prebiotics for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction
Spinal Cord Injuries, Neurogenic Bowel, Bladder Dysfunction
About this trial
This is an interventional treatment trial for Spinal Cord Injuries
Eligibility Criteria
Inclusion Criteria:
- 18 years old
- SCI of at least 3 months duration
- Neurogenic bowel dysfunction scores of >13
Exclusion Criteria:
- Pregnancy
- Inability to understand and respond to the provided questionnaires
- Carcinomas during the last 5 years
- Bowel surgery
- Crohn ́s disease or other bowel conditions
Sites / Locations
- Parkwood InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Human Milk Oligosaccharide (HMO)
Placebo
10 g sachet, self-administered for 3 months. 2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)
10 g sachet, self-administered for 3 months. Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape